HRP20140108T1 - Protutijela protiv sklerostina - Google Patents
Protutijela protiv sklerostina Download PDFInfo
- Publication number
- HRP20140108T1 HRP20140108T1 HRP20140108AT HRP20140108T HRP20140108T1 HR P20140108 T1 HRP20140108 T1 HR P20140108T1 HR P20140108A T HRP20140108A T HR P20140108AT HR P20140108 T HRP20140108 T HR P20140108T HR P20140108 T1 HRP20140108 T1 HR P20140108T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antibody
- functional fragment
- amino acid
- accordance
- Prior art date
Links
- 239000012634 fragment Substances 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 210000000988 bone and bone Anatomy 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 230000037118 bone strength Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102000058171 human SOST Human genes 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (8)
1. Protutijelo, ili njegov funkcionalni fragment, koje se specifično veže na ljudski sklerostin, naznačeno time što protutijelo, ili njegov funkcionalni fragment, sadrži šest CDR-a, čiji su sljedeći aminokiselinski sljedovi: HCDR1, sa SEQ ID NO: 26, HCDR2, sa SEQ ID NO: 27, HCDR3, sa SEQ ID NO: 28, LCDR1, sa SEQ ID NO: 29, LCDR2, sa SEQ ID NO: 30, te LCDR3, sa SEQ ID NO: 31.
2. Protutijelo, ili njegov funkcionalni fragment, u skladu s patentnim zahtjevom 1, naznačeno time što sadrži varijabilno područje teškog lanca i varijabilno područje lakog lanca, gdje varijabilno područje teškog lanca ima aminokiselinski slijed SEQ ID NO: 15, a varijabilno područje lakog lanca ima aminokiselinski slijed SEQ ID NO: 18.
3. Protutijelo, ili njegov funkcionalni fragment, u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačeno time što sadrži polipeptid teškog lanca čiji je aminokiselinski slijed SEQ ID NO: 3 i polipeptid lakog lanca čiji je aminokiselinski slijed SEQ ID NO: 6.
4. Farmaceutski pripravak, naznačen time što sadrži protutijelo u skladu s bilo kojim od prethodnih patentnih zahtjeva, kao i farmaceutski prihvatljivu podlogu ili razrjeđivač.
5. Protutijelo, ili njegov funkcionalni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što je namijenjeno upotrebi kao medikament.
6. Protutijelo, ili njegov funkcionalni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što je namijenjeno upotrebi u povećavanju najmanje jednog od koštane mase, mineralne gustoće kostiju, mineralnog sadržaja kostiju ili čvrstoće kostiju kod ljudskog subjekta.
7. Protutijelo, ili njegov funkcionalni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što je namijenjeno upotrebi u liječenju bolesti ili poremećaja koje se bira između osteoporoze, osteopenije, osteoartritisa, boli povezane s osteoartritisom, reumatoidnog artritisa, bolesti periodonta ili multiplog mijeloma kod ljudskog subjekta.
8. Protutijelo, ili njegov funkcionalni fragment, u skladu s patentnim zahtjevom 7, naznačeno time što je namijenjeno upotrebi u liječenju osteoporoze.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89581307P | 2007-03-20 | 2007-03-20 | |
| PCT/US2008/056527 WO2008115732A2 (en) | 2007-03-20 | 2008-03-11 | Anti-sclerostin antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140108T1 true HRP20140108T1 (hr) | 2014-02-28 |
Family
ID=39756356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140108AT HRP20140108T1 (hr) | 2007-03-20 | 2014-02-05 | Protutijela protiv sklerostina |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US7744874B2 (hr) |
| EP (2) | EP2664346A1 (hr) |
| JP (2) | JP2010524846A (hr) |
| KR (1) | KR101123487B1 (hr) |
| CN (1) | CN101646457B (hr) |
| AU (1) | AU2008229141B2 (hr) |
| BR (1) | BRPI0809026A2 (hr) |
| CA (1) | CA2682212C (hr) |
| CO (1) | CO6230999A2 (hr) |
| CR (1) | CR11004A (hr) |
| CY (1) | CY1114784T1 (hr) |
| DK (1) | DK2131860T3 (hr) |
| DO (1) | DOP2009000223A (hr) |
| EA (1) | EA018204B1 (hr) |
| EC (1) | ECSP099658A (hr) |
| ES (1) | ES2446293T3 (hr) |
| HK (1) | HK1138790A1 (hr) |
| HR (1) | HRP20140108T1 (hr) |
| IL (1) | IL200437A0 (hr) |
| MA (1) | MA31308B1 (hr) |
| MX (1) | MX2009010051A (hr) |
| MY (1) | MY149129A (hr) |
| NZ (1) | NZ578870A (hr) |
| PL (1) | PL2131860T3 (hr) |
| PT (1) | PT2131860E (hr) |
| RS (1) | RS53157B (hr) |
| SI (1) | SI2131860T1 (hr) |
| SV (1) | SV2009003374A (hr) |
| TN (1) | TN2009000383A1 (hr) |
| UA (1) | UA96474C2 (hr) |
| WO (1) | WO2008115732A2 (hr) |
| ZA (1) | ZA200906345B (hr) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040009535A1 (en) * | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| ES2350454T3 (es) | 1998-11-27 | 2011-01-24 | Ucb Pharma S.A. | Composiciones y métodos para incrementar la mineralización de la sustancia ósea. |
| AU2004262640B2 (en) | 2003-06-16 | 2010-12-23 | Ucb Manufacturing, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8461155B2 (en) * | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| SI3345607T1 (sl) | 2006-12-29 | 2023-03-31 | Ossifi-Mab Llc | Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE |
| WO2008115732A2 (en) * | 2007-03-20 | 2008-09-25 | Eli Lilly And Company | Anti-sclerostin antibodies |
| CL2008002775A1 (es) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| AR068767A1 (es) * | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| JP2011506483A (ja) * | 2007-12-14 | 2011-03-03 | アムジエン・インコーポレーテツド | 抗スクレロスチン抗体を用いた骨折の治療方法 |
| AR070141A1 (es) * | 2008-01-23 | 2010-03-17 | Glenmark Pharmaceuticals Sa | Anticuerpos humanizados especificos para el factor von willebrand |
| HRP20240722T1 (hr) | 2008-04-11 | 2024-08-30 | Chugai Seiyaku Kabushiki Kaisha | Molekula koja se veže na antigene, koja se može ponavljano vezati na dvje ili više molekula antigena |
| WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
| BR112012025568A2 (pt) | 2010-04-07 | 2017-03-28 | Abbvie Inc | proteínas de ligação ao tnf-<244>. |
| JP2013525294A (ja) | 2010-04-16 | 2013-06-20 | ノバルティス アーゲー | インプラント骨結合を改善するための方法および組成物 |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| WO2011159704A1 (en) * | 2010-06-14 | 2011-12-22 | Vaccinex, Inc. | Anti-vegf antibodies and uses thereof |
| SG10201505624VA (en) | 2010-11-05 | 2015-09-29 | Novartis Ag | Methods of treating rheumatoid arthritis using il-17 antagonists |
| JP5319651B2 (ja) * | 2010-11-18 | 2013-10-16 | 日本電信電話株式会社 | 分析方法 |
| RU2658504C9 (ru) | 2010-11-30 | 2018-08-21 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул |
| PT2663579T (pt) | 2011-01-14 | 2017-07-28 | Univ California | Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização |
| WO2012118903A2 (en) | 2011-03-01 | 2012-09-07 | Amgen Inc. | Bispecific binding agents |
| MX338078B (es) | 2011-03-25 | 2016-04-01 | Amgen Inc | Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos. |
| PT2699261T (pt) | 2011-04-19 | 2018-10-22 | Amgen Inc | Método para tratamento da osteoporose |
| JP2014515759A (ja) | 2011-04-29 | 2014-07-03 | ノバルティス アーゲー | 扁平上皮がんを治療する方法関連出願 |
| PL2739311T3 (pl) | 2011-08-04 | 2018-08-31 | Amgen Inc. | Metoda leczenia szczelinowych uszkodzeń kości |
| EP2771360A1 (en) * | 2011-10-24 | 2014-09-03 | AbbVie Inc. | Immunobinders directed against sclerostin |
| MX2014004981A (es) | 2011-10-24 | 2014-09-11 | Abbvie Inc | Inmunoaglutinantes dirigidos contra tnf. |
| PE20142245A1 (es) | 2011-10-24 | 2015-01-22 | Abbvie Inc | Inmunoligantes biespecificos dirigidos contra tnf e il-17 |
| WO2013101451A1 (en) | 2011-12-28 | 2013-07-04 | Amgen Inc. | Method of treating alvelor bone loss through the use of anti-sclerostin antibodies |
| WO2014006100A1 (en) | 2012-07-05 | 2014-01-09 | Ucb Pharma S.A. | Treatment for bone diseases |
| US9221904B2 (en) | 2012-07-19 | 2015-12-29 | National Cheng Kung University | Treatment of osteoarthritis using IL-20 antagonists |
| US20140065144A1 (en) * | 2012-08-30 | 2014-03-06 | National Cheng Kung University | Use of il-20 antagonists for promoting bone fracture healing |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014118705A1 (en) | 2013-01-31 | 2014-08-07 | Novartis Ag | Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists |
| AR094877A1 (es) * | 2013-03-08 | 2015-09-02 | Lilly Co Eli | Anticuerpos que se unen a il-23 |
| US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
| US9763911B2 (en) | 2013-12-12 | 2017-09-19 | Mayo Foundation For Medical Education And Research | Prostacyclin compositions for regulation of fracture repair and bone formation |
| AR100270A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Anticuerpos ang2 |
| MA41101A (fr) * | 2014-12-03 | 2017-10-10 | Lilly Co Eli | Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| KR102489471B1 (ko) * | 2014-12-30 | 2023-01-18 | 셀진 코포레이션 | 항-cd47 항체 및 그 용도 |
| AU2016232897B2 (en) * | 2015-03-13 | 2021-05-13 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-sclerostin antibody, antigen binding fragment and medical use thereof |
| IL261200B2 (en) | 2016-03-01 | 2023-03-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Antibodies specific for the human poliovirus receptor |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| AU2017310412A1 (en) | 2016-08-08 | 2019-02-21 | Amgen Inc. | Method of improving connective tissue attachment using anti-sclerostin antibodies |
| KR20190052137A (ko) * | 2016-10-28 | 2019-05-15 | 일라이 릴리 앤드 캄파니 | 항-rankl 항체 및 그의 용도 |
| CA3041684C (en) * | 2016-11-01 | 2023-09-26 | Anaptysbio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| HRP20210207T4 (hr) * | 2016-12-21 | 2025-01-31 | Mereo Biopharma 3 Limited | Uporaba protutijela anti-sklerostin u liječenju osteogenesis imperfecta |
| EP4219563A3 (en) | 2017-01-09 | 2023-10-04 | Tesaro, Inc. | Methods of treating cancer with anti-pd-1 antibodies |
| WO2018139623A1 (en) * | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| WO2018227187A1 (en) * | 2017-06-09 | 2018-12-13 | The Regents Of The University Of California | Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering |
| TW201909913A (zh) | 2017-07-27 | 2019-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種ｓｏｓｔ抗體醫藥組成物及其用途 |
| JP7405764B2 (ja) | 2018-03-30 | 2023-12-26 | アムジエン・インコーポレーテツド | Ｃ末端抗体改変体 |
| GB201810746D0 (en) | 2018-06-29 | 2018-08-15 | Mereo Biopharma 3 Ltd | Use of sclerostin antagonist |
| AU2019316575A1 (en) | 2018-08-10 | 2021-03-04 | Amgen Inc. | Method of preparing an antibody pharmaceutical formulation |
| WO2020154150A1 (en) * | 2019-01-22 | 2020-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
| EP4013786A1 (en) | 2019-08-12 | 2022-06-22 | Amgen Inc. | Anti-sclerostin antibody formulations |
| WO2025019728A1 (en) | 2023-07-19 | 2025-01-23 | Amgen Inc. | Methods of buffer preparation for a therapeutic protein formulation |
| CN119097708A (zh) * | 2024-09-04 | 2024-12-10 | 中国医学科学院北京协和医院 | Dkk1抗体在治疗男性骨质疏松症中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2350454T3 (es) | 1998-11-27 | 2011-01-24 | Ucb Pharma S.A. | Composiciones y métodos para incrementar la mineralización de la sustancia ósea. |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| WO2001098491A2 (en) | 2000-06-19 | 2001-12-27 | F. Hoffmann-La Roche Ag | Osteolevin gene polymorphisms |
| AU2003276430A1 (en) | 2002-06-14 | 2003-12-31 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| WO2004047609A2 (en) * | 2002-11-27 | 2004-06-10 | Visiopharm Aps | A method and a system for establishing a quantity measure for joint destruction |
| AU2004262640B2 (en) * | 2003-06-16 | 2010-12-23 | Ucb Manufacturing, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| WO2005005604A2 (en) | 2003-06-30 | 2005-01-20 | Centocor, Inc. | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
| AU2004324464A1 (en) | 2004-10-22 | 2006-05-04 | Applied Molecular Evolution, Inc. | Methods of optimizing antibody variable region binding affinity |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US20100036091A1 (en) | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| WO2008115732A2 (en) * | 2007-03-20 | 2008-09-25 | Eli Lilly And Company | Anti-sclerostin antibodies |
-
2008
- 2008-03-11 WO PCT/US2008/056527 patent/WO2008115732A2/en active Application Filing
- 2008-03-11 EP EP13178615.4A patent/EP2664346A1/en not_active Withdrawn
- 2008-03-11 JP JP2009554637A patent/JP2010524846A/ja active Pending
- 2008-03-11 BR BRPI0809026-2A2A patent/BRPI0809026A2/pt not_active IP Right Cessation
- 2008-03-11 DK DK08731905.9T patent/DK2131860T3/da active
- 2008-03-11 CN CN2008800091183A patent/CN101646457B/zh active Active
- 2008-03-11 EA EA200970874A patent/EA018204B1/ru not_active IP Right Cessation
- 2008-03-11 RS RS20140033A patent/RS53157B/en unknown
- 2008-03-11 MY MYPI20093894A patent/MY149129A/en unknown
- 2008-03-11 PT PT87319059T patent/PT2131860E/pt unknown
- 2008-03-11 ES ES08731905.9T patent/ES2446293T3/es active Active
- 2008-03-11 KR KR1020097019509A patent/KR101123487B1/ko not_active IP Right Cessation
- 2008-03-11 PL PL08731905T patent/PL2131860T3/pl unknown
- 2008-03-11 UA UAA200909553A patent/UA96474C2/ru unknown
- 2008-03-11 MX MX2009010051A patent/MX2009010051A/es active IP Right Grant
- 2008-03-11 EP EP08731905.9A patent/EP2131860B1/en active Active
- 2008-03-11 CA CA2682212A patent/CA2682212C/en not_active Expired - Fee Related
- 2008-03-11 NZ NZ578870A patent/NZ578870A/en not_active IP Right Cessation
- 2008-03-11 SI SI200831127T patent/SI2131860T1/sl unknown
- 2008-03-11 AU AU2008229141A patent/AU2008229141B2/en not_active Ceased
- 2008-03-11 US US12/160,472 patent/US7744874B2/en active Active
-
2009
- 2009-08-17 IL IL200437A patent/IL200437A0/en unknown
- 2009-08-28 CR CR11004A patent/CR11004A/es unknown
- 2009-09-10 CO CO09097358A patent/CO6230999A2/es active IP Right Grant
- 2009-09-11 ZA ZA2009/06345A patent/ZA200906345B/en unknown
- 2009-09-18 DO DO2009000223A patent/DOP2009000223A/es unknown
- 2009-09-18 TN TNP2009000383A patent/TN2009000383A1/fr unknown
- 2009-09-18 SV SV2009003374A patent/SV2009003374A/es unknown
- 2009-09-28 EC EC2009009658A patent/ECSP099658A/es unknown
- 2009-10-12 MA MA32274A patent/MA31308B1/fr unknown
-
2010
- 2010-05-13 US US12/779,438 patent/US7988970B2/en active Active
- 2010-06-09 HK HK10105734.8A patent/HK1138790A1/xx not_active IP Right Cessation
-
2011
- 2011-06-21 US US13/165,126 patent/US8257704B2/en active Active
-
2013
- 2013-02-22 JP JP2013033583A patent/JP5758933B2/ja active Active
-
2014
- 2014-02-03 CY CY20141100082T patent/CY1114784T1/el unknown
- 2014-02-05 HR HRP20140108AT patent/HRP20140108T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140108T1 (hr) | Protutijela protiv sklerostina | |
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| HRP20191824T1 (hr) | Agonistička sredstva za vezivanje tnf receptora | |
| HRP20201432T1 (hr) | Il-17a sredstvo za vezivanje i njegove uporabe | |
| RU2495050C2 (ru) | Связующий элемент для рецептора gm-csf | |
| ME02798B (me) | Protutijela protiv dkk-1" | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| HRP20211688T1 (hr) | Ljudska protutijela visokog afiniteta za pcsk9 | |
| HRP20180776T1 (hr) | Antagonisti il17c za liječenje upalnih poremećaja | |
| HRP20160151T1 (hr) | PROTUTIJELA PROTIV N3pGlu-AMILOIDNOG BETA PEPTIDA I NJIHOVA UPOTREBA | |
| HRP20140982T1 (hr) | Ljudska anti-il-23 antitijela, pripravci, postupci i upotrebe | |
| RU2010107175A (ru) | Антитела человека к cd20 человека и способ их использования | |
| JP2010526028A5 (hr) | ||
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| JP2011502137A5 (hr) | ||
| PE20081503A1 (es) | Miembros de union para il-6 | |
| JP2016135783A5 (hr) | ||
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| ME02239B (me) | Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta | |
| HRP20171775T1 (hr) | Molekule protutijela koje vežu trombin i njihova uporaba | |
| NZ600512A (en) | Neutralizing prolactin receptor antibodies and their therapeutic use | |
| NZ598391A (en) | Anti-hepcidin antibodies and uses thereof | |
| JP2023093753A5 (hr) | ||
| RU2018120695A (ru) | Связывающие молекулы, специфичные в отношении asct2, и их применения |